🔬 What is the Test?
The FLT3 Mutation Test detects mutations in the FMS-like Tyrosine Kinase 3 (FLT3) gene, which are found in about 30% of Acute Myeloid Leukemia (AML) cases. These mutations, particularly FLT3-ITD (Internal Tandem Duplication) and FLT3-TKD (Tyrosine Kinase Domain mutation), are associated with disease prognosis and treatment decisions.
📊 Normal Ranges:
Negative for FLT3 Mutation → Normal (No FLT3-related AML detected)
Positive for FLT3 Mutation → Suggests AML with FLT3 involvement, influencing treatment and prognosis
(Results should be interpreted with other genetic tests and clinical findings.)
🎯 Purpose of the Test:
✅ Confirms AML Diagnosis and Identifies FLT3 Mutations
✅ Helps assess risk stratification and prognosis
✅ Guides targeted therapy decisions (FLT3 inhibitors like Midostaurin, Gilteritinib)
✅ Monitors treatment response and relapse risk
🩺 When is it Recommended?
🔹 For newly diagnosed AML patients (to determine genetic subtype)
🔹 To assess prognosis (FLT3-ITD mutations are linked to poor outcomes)
🔹 Before starting targeted FLT3 inhibitor therapy
🔹 To monitor treatment response and detect relapse
📝 How is the Test Done?
1️⃣ Sample Collection – Blood or bone marrow sample is taken.
2️⃣ Laboratory Analysis – PCR (Polymerase Chain Reaction) or Next-Generation Sequencing (NGS) detects FLT3 mutations.
3️⃣ Result Interpretation – Determines AML subtype, treatment options, and prognosis.
⚠️ What Do Abnormal Results Mean?
📉 Negative for FLT3 Mutation:
Better prognosis compared to FLT3-mutated AML
Treatment approach depends on other genetic mutations present
📈 Positive for FLT3 Mutation (FLT3-ITD or FLT3-TKD):
FLT3-ITD: Higher risk of relapse, requires FLT3 inhibitor therapy
FLT3-TKD: May still benefit from targeted therapy
Requires close monitoring for treatment response
📌 Infographic Design Idea:
✔ Medical color scheme (red, white, and blue)
✔ Illustration of the FLT3 gene and mutation effects
✔ Flowchart showing AML diagnosis and FLT3-targeted treatment options
✔ Table summarizing FLT3-ITD vs. FLT3-TKD mutations and their clinical impact